Minerva Neurosciences, Inc. (NERV)

USD 2.19

(-5.6%)

Market Cap (In USD)

15.31 Million

Revenue (In USD)

-

Net Income (In USD)

-30 Million

Avg. Volume

17.77 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.06-13.49
PE
-
EPS
-
Beta Value
0.17
ISIN
US6033802058
CUSIP
603380205
CIK
1598646
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Remy Luthringer Ph.D.
Employee Count
-
Website
https://www.minervaneurosciences.com
Ipo Date
2014-07-01
Details
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.